天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium

1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium Struktur
13473-38-6
CAS-Nr.
13473-38-6
Bezeichnung:
1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium
Englisch Name:
1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium
Synonyma:
WPUKUEMZZRVAKZ-UHFFFAOYSA-N;Pipenzolate DISCONTINUED, offer P479853;1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium;1-Ethyl-3-[(hydroxydiphenylacetyl)oxy]-1-methylpiperidinium
CBNumber:
CB0888749
Summenformel:
C22H27NO3
Molgewicht:
353.45468
MOL-Datei:
13473-38-6.mol

1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium Eigenschaften

Sicherheit

1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium Chemische Eigenschaften,Einsatz,Produktion Methoden

Trademarks

Piptal (Marion Merrell Dow);Dropenzil;Pedroacal;Pipenzolate mb san;Piptal pediatrico;pediatrique;Piptalin;.

Weltgesundheitsorganisation (WHO)

Pipenzolate, an anticholinergic agent, was introduced in 1960 for the treatment of spastic conditions of the gastro-intestinal tract. It has never been widely used for the treatment of diarrhoea, and WHO is not aware of any such preparations that remain available.

1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


1-Methyl-3-((hydroxydiphenylace-tyl)-oxy)-1-methyl-piperidinium Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9311 58
Musechem +1-800-259-7612
info@musechem.com United States 4660 60

  • 1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium
  • 1-Ethyl-3-[(hydroxydiphenylacetyl)oxy]-1-methylpiperidinium
  • WPUKUEMZZRVAKZ-UHFFFAOYSA-N
  • Pipenzolate DISCONTINUED, offer P479853
  • 13473-38-6
Copyright 2019 ? ChemicalBook. All rights reserved